Cancer Radiotherapie最新文献

{"title":"Long-term outcomes and cardiac mortality after radiotherapy for primary pulmonary mucosa-associated lymphoid tissue lymphoma","authors":"Pierre Loap ,&nbsp;Youlia Kirova","doi":"10.1016/j.canrad.2026.104827","DOIUrl":"10.1016/j.canrad.2026.104827","url":null,"abstract":"<div><h3>Purpose</h3><div>Pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma is a rare but indolent B-cell lymphoma, most often presenting as localized disease. Radiotherapy is a curative option, but its proximity to the heart raises concerns about long-term cardiac toxicity, which remains poorly documented. The purpose of this work was to evaluate the potential risk of cardiac toxicity following radiotherapy in patients with pulmonary MALT lymphoma.</div></div><div><h3>Patients and methods</h3><div>This retrospective, population-based study used Surveillance, Epidemiology, and End Results (SEER) data (17 registries, 2000–2022; November 2024 submission). We identified patients with primary pulmonary MALT lymphoma treated with radiation. Demographic and clinical characteristics, including age, sex, Ann Arbor stage, tumour laterality, lobe involvement, and treatment modality, were collected. Outcomes included overall survival, cancer-specific survival, cardiac-specific survival, and non-cancer/non-cardiac-specific survival. Survival estimates were generated using Kaplan–Meier methods; univariate and multivariate Cox models assessed factors associated with cardiac-specific mortality.</div></div><div><h3>Results</h3><div>Among 248 patients, the median age was 70 years; 54.0 % were women and 81.9 % Caucasian. Most had early-stage disease (90.3 %) and right-sided tumours (57.3 %). Radiotherapy alone was used in 86.7 %. With a median follow-up of 59 months, median overall survival was 120 months. At 20 years, overall survival rate was 28.9 %, cancer-specific survival rate 85.5 %, and cardiac-specific survival rate 85.0 %. In competing risk multivariate analysis, age greater than 70 years (hazard ratio [HR]: 10.51; 95 % confidence interval [CI]: 1.11–99.8; <em>p</em> <!-->=<!--> <!-->0.040) and stage III–IV (HR: 6.52; 95 % CI: 1.17–36.4; <em>p</em> <!-->=<!--> <!-->0.032) were independently associated with cardiac-specific mortality.</div></div><div><h3>Conclusion</h3><div>Radiotherapy for pulmonary MALT lymphoma is associated with excellent long-term outcomes and low cardiac-specific mortality. Tumour location within the lung does not influence cardiac risk, supporting the absence of significant radiation-induced cardiotoxicity.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 2","pages":"Article 104827"},"PeriodicalIF":1.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148152534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy as a curative strategy for primary pleural indolent lymphomas: Analytical guidelines based on literature and an illustrative population-based case series","authors":"Pierre Loap ,&nbsp;Lise Willems ,&nbsp;Didier Bouscary ,&nbsp;Youlia Kirova","doi":"10.1016/j.canrad.2026.104831","DOIUrl":"10.1016/j.canrad.2026.104831","url":null,"abstract":"<div><h3>Background</h3><div>Primary pleural indolent non-Hodgkin lymphomas, such as marginal zone lymphoma and follicular lymphoma, are rare and understudied. When truly localized, these entities are theoretically curable with radiotherapy, as is the case for other extranodal indolent lymphomas (e.g., orbit, stomach, lung). However, due to their low incidence and frequent diagnostic delays related to nonspecific clinical and radiologic presentations, no standard therapeutic recommendations currently exist. The role of radiotherapy in this setting remains undefined, even in expert guidelines.</div></div><div><h3>Methods</h3><div>We performed a narrative literature review and complemented these findings with a descriptive population-based case series extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Based on these findings and institutional expertise, we developed practical radiotherapy recommendations.</div></div><div><h3>Results</h3><div>Published cases show heterogeneous management strategies, with radiotherapy infrequently used but consistently associated with complete responses. In the SEER cohort, seven patients with stage I–II primary pleural indolent B-cell non-Hodgkin lymphoma (three with a marginal zone lymphoma, three with a follicular lymphoma, and one with a lymphoplasmacytic lymphoma) underwent radiotherapy. Median age was 76 years. With a median follow-up of 91 months (range: 47–172 months), the 10-year cause-specific survival rate was 100 %, and overall survival rate was 83.3 % (95 % confidence interval: 0.583–1.0 %). We propose delivering a dose of 24 to 30<!--> <!-->Gy for curative intent, with reduced-dose strategies (e.g., 2<!--> <!-->×<!--> <!-->2<!--> <!-->Gy with response-adapted completion) in selected patients. Target volumes should encompass the entire pleural mass with 2 to 3<!--> <!-->cm clinical target volume margins, using advanced planning techniques to minimize cardiac and pulmonary exposure.</div></div><div><h3>Conclusions</h3><div>This is the first population-based study evaluating radiotherapy outcomes for primary pleural indolent non-Hodgkin lymphomas. Radiotherapy appears to be a relevant curative option for localized disease. In the absence of formal guidelines, these findings and proposed recommendations may help inform clinical management of this rare but potentially curable lymphoma subtype.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 2","pages":"Article 104831"},"PeriodicalIF":1.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148165863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Magnetic resonance imaging-guided radiotherapy for prostate cancer: A systematic review of the literature","authors":"Sara-Lydia Adoum ,&nbsp;Manon Baty ,&nbsp;Ingrid Masson ,&nbsp;Jennifer Le Guévelou ,&nbsp;Caroline Lafond ,&nbsp;Gilles Créhange ,&nbsp;Olivier Chapet ,&nbsp;David Pasquier ,&nbsp;Olivier Riou ,&nbsp;Gilles Truc ,&nbsp;Naji Salem ,&nbsp;Jean-Marc Simon ,&nbsp;Renaud de Crevoisier","doi":"10.1016/j.canrad.2026.104810","DOIUrl":"10.1016/j.canrad.2026.104810","url":null,"abstract":"<div><div>This systematic literature review explores the potential clinical benefits of magnetic resonance imaging-guided linear accelerator for radiotherapy of prostate cancer, across multiple indications: primary treatment, salvage therapy following radical prostatectomy, reirradiation, and focal boosting of the dominant intraprostatic lesion. Technical considerations related to magnetic resonance imaging-guided radiotherapy are also addressed. Most of the available studies are single-centre or prospective non-randomized trials, with notable methodological heterogeneity regarding irradiation protocols and outcome measures. To date, the MIRAGE trial remains the only published phase III randomized study comparing magnetic resonance imaging-guided radiotherapy to standard stereotactic body radiotherapy. Significant reduction in both acute and late urinary and gastrointestinal toxicity has been demonstrated, attributed to the enhanced precision of imaging-guidance and the reduction in planning target volume margins. However, long-term oncological efficacy remains to be established. Further phase III trials and health economic evaluations are clearly needed to establish the clinical value of this technology. As of today, the implementation of magnetic resonance imaging-guided linear accelerators in routine clinical practice remains limited by technical, organizational, and financial challenges, with accessibility restricted to a limited number of centres and reimbursement strategies yet to be adequately defined.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 2","pages":"Article 104810"},"PeriodicalIF":1.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148152476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cone-beam computed tomography-based radiomics for tumour regression assessment during radiotherapy of non-small-cell lung cancer","authors":"Fan Zhang ,&nbsp;Xutong Li ,&nbsp;Lu Yue ,&nbsp;Yinglin Peng ,&nbsp;Mi Zhou ,&nbsp;Zhiping Luo","doi":"10.1016/j.canrad.2026.104809","DOIUrl":"10.1016/j.canrad.2026.104809","url":null,"abstract":"<div><h3>Purpose</h3><div>During radiotherapy of non-small-cell lung cancers, changes in radiomics features extracted from cone-beam computed tomography images can serve as unique predictors. For adapting treatment plans or assessing early treatment responses, there is a pressing need to screen cone-beam computed tomography-derived radiomics features for predicting tumour regression volume.</div></div><div><h3>Patients and methods</h3><div>Our study enrolled 58 patients with non-small cell lung cancer undergoing radiotherapy, comprising dataset1, and an additional 32 patients who underwent an adaptive treatment approach, forming dataset2. For dataset1 patients, radiomics features were extracted from both the planning computed tomography and the first treatment cone-beam computed tomography. For dataset2 patients, features were also extracted from the replanning computed tomography and the corresponding cone-beam computed tomography after 20 fractions of radiotherapy. By employing correlation coefficient and intraclass correlation coefficient analyses on planning computed tomography and first treatment cone-beam computed tomography features, we identified robust and reproducible features in dataset1 patients. Reproducible delta radiomics features were further selected to characterize feature changes and screen delta radiomics features for tumour regression in dataset2 patients. Lastly, predictive delta radiomics features were screened using least absolute shrinkage and selection operator regression.</div></div><div><h3>Results</h3><div>Based on dataset1, we selected 34 radiomics features. From these, 16 delta radiomics features were further screened using dataset2. The changes observed in these features were consistent across both computed tomography and cone-beam computed tomography images. Specifically, nine features exhibited significant differences (<em>p</em> <!-->&lt;<!--> <!-->0.05) while seven features remained relatively unchanged (<em>p</em> <!-->&gt;<!--> <!-->0.05). Ultimately, four delta radiomics features were identified to classify tumour regression volume with a 30 % threshold for cone-beam computed tomography images.</div></div><div><h3>Conclusion</h3><div>Our study introduces a novel strategy for selecting computed tomography-based cone-beam computed tomography radiomics features, enabling the identification of reliable features for model development. Preliminary findings firstly demonstrate the feasibility of using cone-beam computed tomography-based delta radiomics features to classify tumour regression volume during radiotherapy of non-small-cell lung cancer.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 2","pages":"Article 104809"},"PeriodicalIF":1.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148165883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"White paper on radiotherapy in France: Ten objectives to strengthen one of the major modalities of cancer treatment","authors":"Philippe Giraud ,&nbsp;Véronique Vendrely ,&nbsp;Fabrice Lorchel ,&nbsp;Olivier Chapet","doi":"10.1016/j.canrad.2026.104829","DOIUrl":"10.1016/j.canrad.2026.104829","url":null,"abstract":"<div><div>Radiotherapy is a major component of cancer treatment and contributing to the cure of approximately 220,000 patients annually in France, and to sustained long-term disease control in a substantial proportion of patients. Continuous technological advances – including image-guided radiotherapy, adaptive radiotherapy, and emerging ultra-high dose rate techniques – are transforming clinical practice and improving therapeutic outcomes. However, these innovations also raise important challenges related to equitable access, sustainable financing, workforce capacity, professional training, and the maintenance of high standards of quality and safety. The Société française de radiothérapie oncologique (SFRO; the French society of radiation oncology) conducted a national strategic reflection on the future of radiotherapy in France. Through multidisciplinary consultation involving radiation oncologists, medical physicists, radiation therapists, and healthcare stakeholders, a white paper was developed to assess current challenges and define priorities for the coming years. Four strategic priorities emerged: (i) ensuring equitable access to modern radiotherapy technologies across the national territory; (ii) strengthening patient-centred care and supportive care throughout the treatment pathway; (iii) reinforcing safety and quality frameworks in an increasingly complex technological environment; and (iv) improving workforce planning, training, translational and clinical research, and professional recognition within the radiotherapy field. Ten proposals are outlined to support innovation, strengthen research capacity, modernize financing mechanisms, enhance patient engagement, and address workforce shortages, particularly among radiation therapists and dosimetrists. The recommendations presented in this white paper aim to guide policymakers and healthcare stakeholders in sustaining the development and international competitiveness of radiation oncology in France.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 2","pages":"Article 104829"},"PeriodicalIF":1.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148274226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and outcomes of radiation-induced sarcomas following radiotherapy for low-grade non-Hodgkin lymphomas: A population-based study","authors":"Pierre Loap ,&nbsp;Youlia Kirova","doi":"10.1016/j.canrad.2026.104812","DOIUrl":"10.1016/j.canrad.2026.104812","url":null,"abstract":"<div><h3>Purpose</h3><div>Radiation-induced sarcomas are a rare but serious long-term complication of radiotherapy. While radiotherapy is an effective treatment for low-grade non-Hodgkin lymphomas, the incidence and characteristics of radiation-induced sarcomas in this setting have not been previously described. The purpose of this study was to analyse the incidence and outcomes of radiation-induced sarcomas following radiotherapy for low-grade non-Hodgkin lymphomas.</div></div><div><h3>Patients and methods</h3><div>We conducted a retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER) database (17 registries, 2024 submission) to identify patients diagnosed with follicular or marginal zone lymphoma between 2000 and 2022 who received radiotherapy. Cases of subsequently histologically-confirmed sarcoma were screened and classified as confirmed or possible radiation-induced sarcomas based on anatomical localization and a minimum latency of 3 years. Clinical characteristics, treatments, latency intervals, and survival outcomes were analysed.</div></div><div><h3>Results</h3><div>Among 18,293 patients with low-grade non-Hodgkin lymphomas treated with radiation, 19 developed sarcomas (0.10 %). Ten cases were excluded (eight due to anatomical mismatch, two due to insufficient latency). Of the nine remaining cases, six met criteria for confirmed radiation-induced sarcomas. The median age at lymphoma diagnosis was at least 70<!--> <!-->years, and the median latency to radiation-induced sarcoma was 12<!--> <!-->years (range: 3–20<!--> <!-->years). All sarcomas were localized and treated surgically; three patients also received radiotherapy. After a median follow-up of 78<!--> <!-->months, the 5-year overall survival rate was estimated at 83.3 % (95 % confidence interval: 43.6 %–97.0 %). One patient died from lymphoma progression.</div></div><div><h3>Conclusion</h3><div>Radiation-induced sarcomas following radiotherapy for low-grade non-Hodgkin lymphomas is extremely rare, with favourable outcomes when it occurs. These results provide reassuring data supporting the long-term safety of modern radiotherapy for low-grade non-Hodgkin lymphomas and underscore the importance of continued surveillance and treatment planning in patients with prolonged life expectancy.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 2","pages":"Article 104812"},"PeriodicalIF":1.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148165870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contemporary survival outcomes of patients with isolated nodal recurrences of breast cancer: A population-based study","authors":"Cezara Cheptea ,&nbsp;Youlia Kirova ,&nbsp;Alain Fourquet ,&nbsp;Pierre Loap","doi":"10.1016/j.canrad.2026.104828","DOIUrl":"10.1016/j.canrad.2026.104828","url":null,"abstract":"<div><h3>Purpose</h3><div>Modern adjuvant therapies, including systemic treatments and radiotherapy, have significantly improved outcomes for patients with breast cancer. However, isolated nodal recurrences remain rare, comprising less than 1 % of cases, and pose a therapeutic challenge, with historical 5-year overall survival rates below 50 %. This study evaluated the clinical outcomes of patients with isolated nodal recurrences in the modern era using the Surveillance, Epidemiology, and End Results (SEER) database and examined factors associated with survival.</div></div><div><h3>Materials and methods</h3><div>We analysed data from 1479 female patients with cT0N<!--> <!-->+<!--> <!-->M0 breast cancer diagnosed between 2000 and 2021 in the SEER database. Patients were categorized as having isolated nodal recurrences if they had prior ipsilateral breast cancer or occult primary breast cancer if presenting with a first cancer diagnosis. Demographics, tumour characteristics, and treatments were recorded. Survival outcomes were assessed using Kaplan-Meier and Cox regression models.</div></div><div><h3>Results</h3><div>Of 1479 patients, 42 (2.8 %) had isolated nodal recurrences, and 1437 (97.2 %) had occult primary breast cancer. Median time to isolated nodal recurrences was 105 months. Most initial tumours were early-stage (T1–T2, 75 %) and node-negative (78.6 %). Five-year overall- and cancer-specific survival rates of patients with isolated nodal recurrences were 72.4 % (95 % confidence interval [CI]: 57.6–91.0 %) and 81.5 % (95 % CI: 67.8–97.9 %), respectively, compared to 80.4 and 86.6 % for patients with occult primary breast cancer. Trends toward improved survival with adjuvant chemotherapy (5-year overall survival rates: 78.0 versus 68.0 %) and radiotherapy (5-year overall survival rates: 83.6 versus 63.2 %) were observed but not statistically significant. No survival benefit was found for total mastectomy in cases of isolated nodal recurrences following breast-conserving surgery.</div></div><div><h3>Conclusion</h3><div>This study showed encouraging survival outcomes for patients with isolated nodal recurrences in the modern era, with 5-year overall survival exceeding historical benchmarks. Comparable survival between patients with isolated nodal recurrences and occult primary breast cancer highlights the potential for curative approaches. Further research is required to refine treatment strategies and identify patient subgroups that may benefit from tailored therapies.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 2","pages":"Article 104828"},"PeriodicalIF":1.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148260684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility of a hybrid technique combining dynamic conformal and volumetric-modulated arcs for single-fraction stereotactic radiosurgery of multiple brain tumours: A clinical case study","authors":"Talal Abdul-Hadi,&nbsp;Said Baji,&nbsp;Yasmine Beulque,&nbsp;Edgard Bidja’a Bekonde,&nbsp;Coralie Meurisse,&nbsp;Katrien Thevissen","doi":"10.1016/j.canrad.2026.104832","DOIUrl":"10.1016/j.canrad.2026.104832","url":null,"abstract":"<div><h3>Purpose</h3><div>This dosimetric study investigated the feasibility and effectiveness of a hybrid stereotactic radiosurgery technique combining dynamic conformal and volumetric modulated arcs for treating multiple small brain metastases in a single fraction, using two treatment planning systems: Elements and Monaco.</div></div><div><h3>Materials and methods</h3><div>A clinical case involving multiple brain metastases was selected. Four treatment plans were generated: three using the Elements treatment planning system – (i) a volumetric modulated arc therapy plan (Cranial SRS); (ii) a dynamic conformal arc therapy plan (Multiple Brain Mets); and (iii) a hybrid dynamic conformal arc with volumetric modulated arc therapy plan – and a fourth using the Monaco treatment planning system with a volumetric modulated arc technique. Plans were assessed using quality indices, including target coverage, conformity, gradient and homogeneity indices, and doses to organs at risk. Quality assurance evaluation was performed with the stereotactic radiosurgery StereoPHAN™ phantom, MapCHECK® detector, and EBT-XD™ film. The gamma passing rates were analysed using 3 %/1<!--> <!-->mm criteria. All plans were delivered using a 6 MV flattening filter-free photon beam on a Versa HD™ linear accelerator.</div></div><div><h3>Results</h3><div>The hybrid planning technique demonstrated superior plan quality, with a significant reduction in the volumes of normal brain tissue receiving at least 10<!--> <!-->Gy and 12<!--> <!-->Gy, as well as lower doses to organs at risk, in accordance with established stereotactic radiosurgery guidelines. Quality assurance evaluation confirmed the dosimetric accuracy of the hybrid plan, showing excellent agreement between measured and calculated dose distributions, with a gamma passing rate exceeding 98 %.</div></div><div><h3>Conclusion</h3><div>For single-isocentre, multitarget stereotactic radiosurgery, the hybrid technique could represent a promising approach, offering improved sparing of surrounding normal tissues and consistent plan quality. However, these results need to be validated in larger clinical cases.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 2","pages":"Article 104832"},"PeriodicalIF":1.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148039410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary uveal diffuse large B-cell lymphoma: A population-based study","authors":"Pierre Loap,&nbsp;Youlia Kirova,&nbsp;Rémi Dendale","doi":"10.1016/j.canrad.2026.104830","DOIUrl":"10.1016/j.canrad.2026.104830","url":null,"abstract":"<div><h3>Purpose</h3><div>Primary involvement of the uveal tract by diffuse large B-cell lymphoma is exceedingly rare and poorly characterized. Most reported ocular lymphomas in this location are indolent mucosa-associated lymphoid tissue lymphomas with favourable outcomes. We aimed to evaluate the epidemiologic and clinical features of primary uveal diffuse large B-cell lymphoma using a large population-based dataset.</div></div><div><h3>Material and methods</h3><div>We performed a retrospective analysis of cases recorded between 2000 and 2022 in the Surveillance, Epidemiology, and End Results (SEER) database. Eligible patients had histologically confirmed diffuse large B-cell lymphoma with primary localization in the choroid (C69.3) or ciliary body/iris (C69.4). Localized primary uveal diffuse large B-cell lymphoma was defined as Ann Arbor stage I disease without systemic involvement. Survival outcomes were analysed using Kaplan–Meier estimates and Cox univariate models.</div></div><div><h3>Results</h3><div>Among 134,366 diffuse large B-cell lymphoma cases, 51 involved the uveal tract (0.038 %), with 42 (82.4 %) classified as localized primary uveal diffuse large B-cell lymphoma. Median age was 65 years; most patients were Caucasian. The 5-year overall survival and cancer-specific survival rates were 45.5 % and 58.4 %, respectively. For patients with localized diseases, 5-year cancer-specific survival rate was 59.4 %, with a survival plateau beyond 6 years. No significant associations were found between overall- or cancer-specific survival and clinical or treatment variables, including radiotherapy or chemotherapy.</div></div><div><h3>Conclusions</h3><div>Primary uveal diffuse large B-cell lymphoma is an ultra-rare and aggressive malignancy, distinct from uveal mucosa-associated lymphoid tissue lymphoma. While outcomes are poorer, a subset of patients with localized disease may achieve long-term remission. Radiotherapy may be a treatment alternative for selected patients, though optimal management remains undefined. Further prospective studies are warranted.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 2","pages":"Article 104830"},"PeriodicalIF":1.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148039411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors affecting the stability of deep inspiration breath-holding in radiotherapy for left-sided breast cancers","authors":"Qianqian Xuan,&nbsp;Qing Xu","doi":"10.1016/j.canrad.2026.104813","DOIUrl":"10.1016/j.canrad.2026.104813","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Purpose&lt;/h3&gt;&lt;div&gt;The purpose of this study was to explore the factors affecting the stability of deep inspiration breath-hold for left-sided breast cancer radiotherapy and provide directional suggestions for clinicians to consider whether patients with left-sided breast cancer were fit for this technique.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;The purpose of this study was to explore the factors affecting the stability of deep inspiration breath-hold for left-sided breast cancer radiotherapy and provide directional suggestions for clinicians to consider whether patients with left-sided breast cancer were fit for this technique.&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Material and methods&lt;/h3&gt;&lt;div&gt;Using optical body surface monitoring system, 100 patients with left-sided breast cancer were trained for deep inspiration breath-hold before computed tomography positioning. The patients’ age, height, weight, vital capacity, type of surgery (modified radical or breast-conserving operation) were recorded. According to the duration and fluctuation of each inspiration, the patients were divided into five categories. The statistical methods of Spearman and Kendall were used to calculate correlation coefficients, and the &lt;em&gt;p&lt;/em&gt; values of these factors and breath-holding stability grades were calculated using the Spss software; the correlation heat map was drawn by Origin software, reflecting which of the above factors had significant correlation with breath-holding stability and their correlation strength.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;Using optical body surface monitoring system, 100 patients with left-sided breast cancer were trained for deep inspiration breath-hold before computed tomography positioning. The patients’ age, height, weight, vital capacity, type of surgery (modified radical or breast-conserving operation) were recorded. According to the duration and fluctuation of each inspiration, the patients were divided into five categories. The statistical methods of Spearman and Kendall were used to calculate correlation coefficients, and the &lt;em&gt;p&lt;/em&gt; values of these factors and breath-holding stability grades were calculated using the Spss software; the correlation heat map was drawn by Origin software, reflecting which of the above factors had significant correlation with breath-holding stability and their correlation strength.&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Values of &lt;em&gt;p&lt;/em&gt; inferior to 0.05 were obtained for vital capacity, body mass index, age and surgical method, and values of &lt;em&gt;p&lt;/em&gt; greater than 0.05 were obtained for adjuvant chemotherapy and targeted treatment. According to the value of correlation coefficient and correlation heat map, the order of strength is vital capacity&lt;!--&gt; &lt;!--&gt;&gt;&lt;!--&gt; &lt;!--&gt;body mass index&lt;!--&gt; &lt;!--&gt;&gt;&lt;!--&gt; &lt;!--&gt;age&lt;!--&gt; &lt;!--&gt;&gt;&lt;!--&gt; &lt;!--&gt;surgical method.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;Values of &lt;em&gt;p&lt;/em&gt; inferior to 0.05 were obtained for vital capacity, body mass index, age and surgical method, and values of &lt;em&gt;p&lt;/em&gt; greater than 0.05 were obtained for adjuvant ch","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 2","pages":"Article 104813"},"PeriodicalIF":1.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148229669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}